Welcome to our dedicated page for ELI LILLY & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ELI LILLY & Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ELI LILLY & Co's regulatory disclosures and financial reporting.
Juan R. Luciano, a director of Eli Lilly & Co. (LLY), reported an acquisition on 08/18/2025 recorded on a Form 4. The filing shows a Code V transaction (shares acquired pursuant to a plan) and lists 16,403.184 as the amount of securities beneficially owned following the reported transaction. The filing also references $698.05 and includes an explanatory note that the shares acquired were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common stock after the reporting person’s separation from service.
Mary Lynne Hedley, a director of Eli Lilly & Co. (LLY), reported a transaction on 08/18/2025 in which shares were acquired under the companys director deferral arrangements. The filing shows an acquisition (Code A) of 14.206 units at a reported price of $698.05. The report lists 1,986.78 shares beneficially owned following the transaction, with ownership reported as direct and indirect (by trust) where applicable. The filing explains the shares were deferred in lieu of cash compensation as stock units under the Lilly Directors Deferral Plan and will be settled in common stock after the reporting persons separation from service. The reporting person disclaims beneficial ownership except to the extent of pecuniary interest.
J. Erik Fyrwald, a director of Eli Lilly & Co. (LLY), reported acquiring 74,591.985 shares of the company's common stock on 08/18/2025 at a per-share price of $698.05. The filing states these shares were elected to be deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in shares following the reporting person’s separation from service. The transaction is reported as an acquisition of non-derivative common stock via Code A (acquisition).
Ralph Alvarez, a director of Eli Lilly & Co. (LLY), reported a non-derivative acquisition on 08/18/2025. The filing shows an acquisition entry with notation "16.833(1) A $698.05 55,011.413 D" and indicates 758 shares are held indirectly by trust. The reporting person elected to defer the acquired shares as stock units under the Lilly Directors' Deferral Plan; those units will be settled in common stock following his separation from service. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest. The form was signed on 08/19/2025.
Eli Lilly executive Lucas E. Montarce reported an open-market purchase of 715 shares of Eli Lilly common stock at a weighted-average price of $691.786, executed in multiple trades at prices between $691.67 and $691.90. After the reported purchases, the reporting person beneficially owns 14,684.736 shares of the company's common stock. The filing identifies the reporting person as an officer (EVP & CFO) and includes an undertaking to provide details of the number of shares bought at each separate price within the stated range upon request.
Ralph Alvarez, a director of Eli Lilly & Co. (LLY), reported an acquisition of company common stock. The Form 4 discloses that on 08/13/2025 he purchased 758 shares at a price of $660.254 per share. After the reported transaction, the filing lists 54,994.58 shares as beneficially owned, held indirectly through a trust. The report includes the standard disclaimer that the reporting person disclaims beneficial ownership except to the extent of pecuniary interest. The form was signed on 08/14/2025 by an authorized filer on behalf of Mr. Alvarez.
Jacob Van Naarden, EVP & President, Lilly Oncology, reported an acquisition of 1,000 shares of Eli Lilly & Co. (LLY) on 08/13/2025 at a reported price of $647.36 per share. The Form 4 shows the reporting person’s direct beneficial ownership following the transaction as 20,561.985 shares.
The filing also lists indirect holdings of 4,342 shares held by the Van Naarden Family Trust and 4,302 shares held by the reporting person’s spouse. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest. The form is signed by Jonathan Groff on behalf of Jacob Van Naarden, dated 08/13/2025.
David A. Ricks, President, Chair and CEO of Eli Lilly & Co., reported an open-market purchase of common stock. The Form 4 shows a purchase of 1,632 shares on 08/12/2025 at a weighted average price of $644.769 per share, with individual trade prices in the range $644.45 to $645.11. Following the reported transaction the filing shows 546,601.167 shares beneficially owned by the reporting person.
The filing also discloses indirect holdings: 54,117 shares in a 2022 GRAT, 300 shares by a Trust, 68,656 shares by a SLAT, and 7,295.84 shares in a 401(k). Footnotes state 16 shares from a family member's retirement account are included and that 5,340 shares were transferred to the reporting person on May 15, 2025 as an annuity payment under the GRAT.
Daniel Skovronsky, EVP, Chief Scientific Officer and President of LRL & LLY Imm at Eli Lilly & Co (LLY), reported a purchase on 08/12/2025 of 1,000 shares of common stock on Form 4. The transaction is coded P for purchase at a weighted average price of $634.405 with execution prices ranging from $634.21 to $634.42. After the reported purchase the filing shows 137,660.112 shares beneficially owned directly. The filing also discloses indirect holdings of 72,359 shares by a trust, 747 shares by the reporting person’s spouse, and 2,510 shares held in a spousal lifetime access trust transferred on March 10, 2025. The filer disclaims beneficial ownership except to the extent of pecuniary interest.
Gabrielle Sulzberger, a director of Eli Lilly & Co. (LLY), reported acquiring 117 shares of common stock on 08/12/2025 under transaction code P. The reported price was $641.182 per share and her direct holdings after the trade were 2,703.055 shares. The Form 4 was filed by one reporting person.